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Background: Early insulin resistance without diabetes can cause cardiovascular
disease, which is a public health challenge. This study aimed to investigate the effects
of the triglyceride to high-density lipid (HDL)-cholesterol ratio (TG/HDL-C), which could
reflect insulin resistance from the beginning, on the incident risk of ischemic heart
disease (IHD).
Methods: We assessed 16,455 individuals (8,426 men and 8,029 women) without
diabetes in a community-dwelling Korean cohort using National Health Insurance
data. Participants were classified based on the TG/HDL-C quartiles. Using multivariate
Cox proportional-hazards regression models, we prospectively examined the hazard
ratios (HRs) with 95% confidence intervals (CIs) for IHD over 50 months after
baseline enrolment.
Results: During the follow-up period, 321 (2.0%) participants developed IHD. After
adjusting for potential confounding variables, the HRs of IHD for TG/HDL-C quartiles
were 1.00, 1.61 (95% CI, 1.05–2.48), 1.85 (95% CI, 1.21–2.81), and 2.29 (95% CI,
1.50–3.51), respectively. Compared with men, women showed higher HRs for the risk of
incident IHD in the fourth quartile [HR (95% CI) = 2.98 [1.50–5.88] and 1.80 [1.02–3.17],
respectively). Compared with metabolic syndrome, TG/HDL-C had a more powerful
predictive value for IHD.
Conclusions: In Koreans without diabetes, an increased TG/HDL-C precedes future
IHD. Additionally, sex differences may merit serious consideration when interpreting
TG/HDL-C for assessing cardiovascular risks in clinical practice.
Keywords: triglyceride to HDL-cholesterol ratio, cardiometabolic risk, insulin resistance, ischemic heart disease,
cohort study
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INTRODUCTION
Ischemic heart disease (IHD) is a significant challenge
among middle-aged individuals without diabetes. From an
epidemiological perspective, patients without diabetes who have
IHD can have a poorer prognosis than patients with diabetes
(1–3). There may be a significant decline in insulin sensitivity
over approximately 5 years as a natural course of β-cell function,
even among individuals with normal glucose tolerance or in
a pre-diabetic state (4). Additionally, coronary heart disease
can begin in early-stage insulin resistance (5), which may be
overlooked in clinical settings. Therefore, management of IHD
risk factors in the preclinical stage is important from a public
health perspective, which facilitates disease prevention and
delays IHD progression.
Individuals with early insulin resistance often have increased
and decreased triglyceride (TG) and high-density lipoprotein
cholesterol (HDL-C) levels, respectively (6). Epidemiological
studies have reported the predictive utility of the TG to HDL-
C ratio (TG/HDL-C) for type 2 diabetes, which suggests that it is
a simple and more accessible marker of insulin resistance from
onset compared with homeostasis model assessment of insulin
resistance or hyperinsulinemic-euglycemic clamp testing (7–9).
Furthermore, TG/HDL-C is closely associated with small dense
low-density lipoprotein cholesterol (LDL-C) levels, which have
atherogenic properties (10, 11).
A recent study reported that a higher TG/HDL-C
ratio is associated with the subclinical burden of coronary
atherosclerosis (12). Previous prospective studies have primarily
focused on cardiovascular mortality or individuals with some
cardiovascular risks (13–16). Additionally, sex differences in
these relationships remain unclear. This prospective study aimed
to investigate the relationship between the TG/HDL-C ratio
and incident IHD in a large-scale, community-dwelling, Korean
cohort without diabetes, using National Health Insurance
Service data.
MATERIALS AND METHODS
Study Design and Participants
This study is a derivative of the Health Risk Assessment
Study (HERAS), which was designed to identify and explore
surrogate indicators for cardiometabolic diseases among Korean
adults (17, 18). The HERAS cohort is comprised of 20,530
participants who sequentially visited the Health Promotion
Center, Yonsei University Gangnam Severance Hospital, for
health examination between November 1, 2006, and June
8, 2010. Among the participants identified at baseline, we
excluded 1,590 individuals previously diagnosed with angina
pectoris, myocardial infarction, ischemic stroke, diabetes
mellitus, or newly developed type 2 diabetes (defined as a fasting
plasma glucose level ≥ 126 mg/dl). Additionally, we excluded
participants according to the following criteria: aged < 30
years, current use of dyslipidemia medication or aspirin, and
high-sensitivity C-reactive protein (hsCRP) level ≥ 10 mg/L (n
= 2,485). Consequently, 16,455 individuals were included in the
final analysis (Figure 1).
Data Collection
Each participant completed a lifestyle behavior and medical
history questionnaire, which included information regarding
cigarette smoking, alcohol intake, and physical activity. Smoking
status was defined using the following categories: non-smoker,
ex-smoker, and current smoker. Regular alcohol intake was
defined as an alcohol consumption rate of ≥ 140 g/week.
Regular exercise was defined as moderate physical activity ≥
thrice per week. Bodyweight and height were measured to the
nearest 0.1 kg and 0.1 cm, respectively, in light indoor clothing
without footwear. The body mass index was calculated as the
weight in kilograms divided by the square of the height in
meters (kg/m2). Systolic and diastolic blood pressures were
measured on the patient’s right arm using a standard mercury
sphygmomanometer in the sitting position after 10min of rest
(Baumanometer, W.A. Baum Co., Inc., Copiague, NY, USA).
The mean arterial pressure was calculated from the systolic
and diastolic blood pressures and weighted as 1/3 systolic and
2/3 diastolic blood pressure (19). Blood samples were obtained
from the antecubital vein after overnight 12-h fasting. Fasting
plasma glucose, total cholesterol, triglyceride, and HDL-C levels
were measured through enzymatic methods using a Hitachi
7,600 automated chemistry analyzer (Hitachi Co., Tokyo, Japan).
Serum hsCRP levels were measured with a Roche/Hitachi 912
System using a latex-enhanced immunoturbidimetric method
(Roche Diagnostics, Indianapolis, IN, USA). Hypertension was
defined as a systolic and diastolic blood pressure ≥ 140 and
≥ 90 mmHg, respectively, or current hypertension medication
use (20). Impaired fasting glucose was defined as a fasting
plasma glucose level of 100–126 mg/dl (21). Metabolic syndrome
was defined using the modified National Cholesterol Education
Program Adult Treatment Panel III. Since we did not measure
the waist circumference, obesity was defined as BMI ≥ 25
kg/m2, as suggested by the position statement of the American
College of Endocrinology (22). Metabolic syndrome was defined
as the presence of ≥ 3 of the following risk factors: obesity
with BMI ≥ 25.0 kg/m2, elevated systolic blood pressure ≥ 130
mmHg, elevated diastolic blood pressure≥85mmHg, or using an
antihypertensivemedication; high fasting plasma glucose levels≥
100 mg/dl or using diabetes medication; triglyceride levels ≥ 150
mg/dl; and HDL cholesterol levels< 40 mg/dl and<50 mg/dl for
men and women, respectively. TG/HDL-C was calculated as TG
(mg/dl) divided by HDL-C level (mg/dl). TG/HDL-C values were
categorized into quartiles as follows: Q1 (≤1.25), Q2 (1.26–1.98),
Q3 (1.99–3.24), and Q4 (≥ 3.25).
Study Outcomes
The primary outcome was IHD, which comprised of angina
pectoris (ICD-10 code I20) or acute myocardial infarction (ICD-
10 code I21) occurring after study enrolment (17, 18). To define
baseline and post-survey outcomes, we linked a personal 13-
digit identification number for each participant that was assigned
using the Health Insurance Review and Assessment Data (HIRA)
in Korea, which is a repository of claims data collected while
reimbursing healthcare providers, from November 1, 2006, to
December 31, 2010.
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FIGURE 1 | Flowchart for the selection of study participants.
Statistical Analysis
Baseline characteristics were compared among the TG/HDL-
C quartiles using analysis of variance (ANOVA) and the
chi-squared test for continuous and categorical variables,
respectively. Moreover, we performed sex-based comparisons of
the clinical and biochemical characteristics using independent
two-sample t-tests and a chi-square test. Kaplan–Meier curves
were used to assess the cumulative incidence of IHD. The
log-rank test was used for among-group comparisons of the
distribution of the cumulative IHD incidence. In multivariate
analysis, after setting the lowest TG/HDL-C quartile as a
reference group, the hazard ratios (HRs) and 95% confidence
intervals (CIs) for incident IHD were calculated using the
Cox proportional hazards regression model after adjusting
for potential confounding variables. Pairwise comparisons of
receiver-operating characteristic (ROC) curves were used to
compare the areas under ROC curves (AUC) for IHD incidence
based on TG/HDL-C, presence of metabolic syndrome, and
the number of metabolic syndrome components. Furthermore,
we used AUC values to test the sensitivity and specificity of
the biomarkers for predicting IHD. All statistical analyses were
performed using SAS version 9.4 software (; SAS Institute Inc.,
Cary, NC, USA) and all statistical tests were two-sided. Statistical
significance was set at p < 0.05.
RESULTS
Baseline Characteristics of the Study
Population
Table 1 shows the baseline characteristics of the study population
(n = 16,455; 8,426 men and 8,029 women) based on the
TG/HDL-C quartiles. The mean age, BMI, TG levels, HDL-C
levels, and TG/HDL-C were 46.1 ± 9.5 years, 23.4 ± 3.0 kg/m2,
124.2± 84.9, 53.2± 12.6, and 2.64± 2.42 mg/dl, respectively.
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TABLE 1 | Baseline characteristics of the study population according to the TG/HDL-C quartiles.
Characteristics TG/HDL-C quartiles
Overall Q1 Q2 Q3 Q4 P-valuea Post-hocb
(n = 16,455) (n = 4,112) (n = 4,147) (n = 4,081) (n = 4,115)
TG/HDL-C 2.64 ± 2.42 ≤1.25 1.26–1.98 1.99–3.24 ≥ 3.25
Age (years) 46.1 ± 9.5 44.4 ± 9.2 46.3 ± 9.5 47.0 ± 9.5 46.6 ± 9.6 <0.001 a,b,c,d
Male sex (%) 51.2 24.8 43.0 61.2 76.0 <0.001 -
Body mass index (kg/m2 ) 23.4 ± 3.0 21.5 ± 2.5 22.8 ± 2.7 24.1 ± 2.8 25.1 ± 2.7 <0.001 a,b,c,d,e,f
Systolic blood pressure (mmHg) 121.9 ± 15.5 115.8 ± 14.5 120.1 ± 15.1 124.2 ± 15.0 127.7 ± 14.7 <0.001 a,b,c,d,e,f
Diastolic blood pressure (mmHg) 76.2 ± 10.1 72.1 ± 9.4 75.0 ± 9.7 77.7 ± 9.8 80.1 ± 9.6 <0.001 a,b,c,d,e,f
Fasting plasma glucose (mg/dl) 91.4 ± 9.8 87.8 ± 8.8 90.5 ± 8.9 92.7 ± 9.6 94.7 ± 10.3 <0.001 a,b,c,d,e,f
Total cholesterol (mg/dl) 190.3 ± 33.3 181.7 ± 30.7 185.8 ± 31.5 194.0 ± 33.0 199.6 ± 34.9 <0.001 a,b,c,d,e,f
Triglyceride (mg/dl) 124.2 ± 84.9 60.6 ± 13.1 87.9 ± 16.4 123.3 ± 23.8 225.2 ± 110.8 <0.001 a,b,c,d,e,f
HDL-cholesterol (mg/dl) 53.2 ± 12.6 66.0 ± 11.3 55.5 ± 9.2 49.2 ± 8.1 42.1 ± 7.1 <0.001 a,b,c,d,e,f
C-reactive protein (mg/L) 1.0 ± 1.3 0.7 ± 1.1 0.9 ± 1.3 1.2 ± 1.4 1.4 ± 1.5 <<0.001 a,b,c,d,e,f
Current smoker (%) 24.7 10.2 18.6 28.8 40.9 <0.001 -
Alcohol drinking (%) 43.3 35.0 40.0 45.9 52.4 <0.001 -
Regular exercise (%) 30.9 33.5 33.8 30.1 26.3 <0.001 -
Hypertension (%) 20.3 10.9 16.1 23.7 30.7 <0.001 -
Impaired fasting glucose (%) 18.0 12.0 19.7 29.3 39.1 <0.001 -
Metabolic syndrome (%) 12.1 0.6 2.4 8.0 37.5 <0.001 -
aP-values were calculated using 1-way ANOVA or Pearson’s chi-square test.
bPost-hoc analysis with the Bonferroni method: a, Q1 vs. Q2; b, Q1 vs. Q3; c, Q1 vs. Q4; d, Q2 vs. Q3; e, Q2 vs. Q4; and f, Q3 vs. Q4.
TABLE 2 | Clinical and biochemical characteristics according to sex.
Men Women P-value*
(n = 8,426) (n = 8,029)
TG/HDL-C 3.33 ± 2.91 1.91 ± 1.44 <0.001
Age (years) 45.9 ± 9.5 46.2 ± 9.5 0.037
Body mass index (kg/m2 ) 24.3 ± 2.8 22.4 ± 2.9 <0.001
Systolic blood pressure (mmHg) 126.3 ± 14.3 117.4 ± 15.4 <0.001
Diastolic blood pressure (mmHg) 79.4 ± 9.4 72.9 ± 9.7 <0.001
Mean arterial pressure (mmHg) 95.0 ± 10.7 87.7 ± 11.2 <0.001
Fasting plasma glucose (mg/dl) 93.5 ± 9.9 89.3 ± 9.2 <0.001
Total cholesterol (mg/dl) 192.4 ± 32.8 188.0 ± 33.7 <0.001
Triglyceride (mg/dl) 147.9 ± 100.0 99.3 ± 55.4 <0.001
HDL-cholesterol (mg/dl) 49.0 ± 11.0 57.7 ± 12.7 <0.001
C-reactive protein (mg/L) 1.2 ± 1.4 0.9 ± 1.2 <0.001
Current smoker (%) 42.2 5.5 <0.001
Alcohol drinking (%) 60.5 49.9 <0.001
Regular exercise (%) 32.0 29.8 0.002
Hypertension (%) 26.1 14.3 <0.001
Impaired fasting glucose (%) 23.6 12.1 <0.001
Metabolic syndrome (%) 13.0 11.1 <0.001
*p values were calculated using an independent two-sample t-test or Pearson’s
chi-squared tests.
The group with the highest TG/HDL-C quartile showed the
highest mean values of BMI, mean arterial pressure, fasting
plasma glucose, total cholesterol, and hsCRP levels, as well as
the lowest mean HDL-C levels. Moreover, this group showed the
highest proportions of current smokers and alcohol drinkers, as
well as the lowest proportion of individuals involved in regular
exercise. The prevalence of hypertension, impaired fasting
glucose, and metabolic syndrome were 20.3, 18.0, and 12.1%,
respectively, which gradually increased according to TG/HDL-
C quartiles. There was no sex difference in the age distribution;
however, men showed a higher TG/HDL-C than women (3.33 ±
2.91 vs. 1.91± 1.44; Table 2).
Cumulative Ischemic Heart Disease
Incidence
During the follow-up period, 321 (2.0%, 321/16,455) individuals
developed IHD. The IHD incidence rate (per 1,000 person-
years) was positively correlated with the TG/HDL-C quartiles.
The higher TG/HDL-C groups showed a significantly increased
cumulative IHD incidence over 50 months following the baseline
survey (log-rank test, P < 0.001) (Figure 2).
Hazard Ratios for Incident Ischemic Heart
Diseases
Tables 3, 4 show the results of the Cox proportional hazards
regression analysis for predicting IHD based on the TG/HDL-C
quartiles. Compared with the reference first TG/HDL-C quartile,
the HRs of incident IHD for the second, third, and fourth
quartiles increased in a dose-dependent manner. The HRs for
incident IHD were 1.64 (95% CI, 1.07–2.52), 1.85 (95% CI,
1.21–2.83), and 2.35 (95% CI, 1.53–3.60) in the second, third
and fourth TG/HDL-C quartiles, respectively, after adjusting
for age, sex, BMI, smoking status, alcohol intake, and physical
activity. Similarly, these longitudinal positive associations were
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FIGURE 2 | Kaplan-Meier plots indicating the cumulative probability of being diagnosed with ischemic heart disease after the baseline survey.
observed after additionally adjusting for systolic blood pressure,
diastolic blood pressure, fasting plasma glucose, hsCRP levels,
and hypertension medication. The corresponding adjusted HR
for the highest vs. lowest TG/HDL-C quartile was 2.26 (95% CI,
1.47–3.48). Sex-based subgroup analysis revealed that the HRs of
incident IHD for the fourth quartile were higher in women than
in men [HR (95% CI) = 2.98 [1.51–5.89] and 1.81 [1.03–3.20],
respectively) (Model 3, Figure 3).
Pairwise Comparison With Metabolic
Syndrome Parameters
Pairwise comparison of receiver operating characteristic (ROC)
analysis for incident IHD revealed that the AUC of TG/HDL-
C was significantly higher than that of metabolic syndrome (P
<0.001), which was similar to that of the number of metabolic
syndrome components (P = 0.929). In the longitudinal model,
the AUC, sensitivity, and specificity of TG/HDL-C were 0.607,
64.2, and 52.1%, respectively (Table 5).
DISCUSSION
This large-scale cohort study on community-dwelling Koreans
without diabetes over a 50-month period found that higher
TG/HDL-C values were associated with IHD incidence, which
remained after adjustment for lifestyle factors, inflammation, and
hypertension medication. Moreover, compared with metabolic
syndrome, TG/HDL-C had a more powerful predictive value
for IHD.
The association between TG/HDL-C and incident IHD was
more prominent in women than in men. Additionally, the HRs
of incident IHD in women significantly increased according to
the TG/HDL-C quartiles; contrastingly, those in men did not
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TABLE 3 | Univariate and multivariate Cox proportional-hazards regression models for incident ischemic heart disease.
Variables Univariate Multivariate
HRs 95% CIs P-value HRs 95% CIs P-value
Age, years 1.07 1.06–1.08 <0.001 1.06 1.04–1.07 <0.001
Male sex, yes or no 1.60 1.28–2.01 <0.001 1.50 1.06–2.12 0.023
Body mass index, kg/m2 1.09 1.05–1.13 <0.001 1.03 0.98–1.08 0.249
Current smoking, yes or no 1.15 0.86–1.55 0.338 1.04 0.72–1.51 0.840
Alcohol drinking, yes or no 0.76 0.60–0.96 0.019 0.77 0.59–1.00 0.047
Regular exercise, yes or no 1.43 1.13–1.80 0.002 1.19 0.94–1.52 0.151
Systolic blood pressure, mmHg 1.02 1.01–1.02 <0.001 1.00 0.99–1.02 0.885
Diastolic blood pressure, mmHg 1.02 1.01–1.03 <0.001 0.99 0.97–1.02 0.501
Fasting plasma glucose, mg/dl 1.03 1.02–1.04 <0.001 1.01 1.00–1.02 0.048
C-reactive protein, mg/L 1.07 1.00–1.15 0.052 0.94 0.86–1.03 0.213
Hypertension medication, yes or no 3.22 2.44–4.24 <0.001 1.83 1.34–2.49 <0.001
TG/HDL-C quartiles, Q1 vs. Q4 2.99 2.08–4.29 <0.001 2.26 1.47–3.48 <0.001
TABLE 4 | Hazard ratios and 95% confidence intervals for new-onset ischemic heart diseases according to TG/HDL-C quartiles.
TG/HDL-C quartiles P for trend
Q1 Q2 Q3 Q4
New cases of ischemic heart disease, n 39 73 91 118
Mean follow-up, years 2.4 ± 1.1 2.4 ± 1.1 2.4 ± 1.1 2.4 ± 1.1
Pearson-years of follow-up 9,682 9,834 9,676 9,839
Incidence rate/1,000 person –years 4.0 7.4 9.4 12.0
Model 1 1.00 (reference) 1.64 (1.07–2.52) 1.85 (1.21–2.83) 2.35 (1.53–3.60) 0.001
Men 1.00 (reference) 1.41 (0.79–2.54) 1.55 (0.88–2.74) 1.89 (1.07–3.32) 0.137
Women 1.00 (reference) 1.85 (0.99–3.45) 2.14 (1.12–4.12) 2.98 (1.52–5.84) 0.017
Model 2 1.00 (reference) 1.63 (1.06–2.50) 1.82 (1.19–2.79) 2.30 (1.49–3.53) 0.002
Men 1.00 (reference) 1.41 (0.78–2.54) 1.55 (0.88–2.74) 1.86 (1.05–3.28) 0.164
Women 1.00 (reference) 1.85 (0.99–3.45) 2.10 (1.09–4.05) 2.95 (1.50–5.82) 0.020
Model 3 1.00 (reference) 1.63 (1.07–2.51) 1.82 (1.19–2.79) 2.26 (1.47–3.48) 0.003
Men 1.00 (reference) 1.42 (0.79–2.56) 1.54 (0.87–2.72) 1.81 (1.03–3.20) 0.209
Women 1.00 (reference) 1.86 (0.99–3.47) 2.13 (1.10–4.09) 2.98 (1.51–5.89) 0.019
Model 1: adjusted for age, sex, body mass index, smoking status, alcohol intake, and physical activity.
Model 2: adjusted for age, sex, body mass index, smoking status, alcohol intake, physical activity, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, and high
sensitivity C-reactive protein.
Model 3: adjusted for age, sex, body mass index, smoking status, alcohol intake, physical activity, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, high
sensitivity C-reactive protein, and hypertension medication.
exhibit significant trends. Cheng et al. conducted a prospective
study on 11,946 Chinese individuals without diabetes found
that the risk for type 2 diabetes increased by approximately
30% with 1-unit of the TG/HDL-C increment (8). Moreover,
they observed a clearer dose-response relationship in women
than in men. Regarding cardiovascular disease (CVD), studies
conducted in men and women separately have established this
relationship. Hadaegh et al. (23) showed that Iranian men in
the highest TG/HDL-C quartile had a 1.75-fold higher risk
of coronary heart disease over a median follow-up period of
6.5 years compared with the reference low quartile. Another
longitudinal study conducted by Bittner et al. reported a
positive relationship between the TG/HDL-C and suspected
CVD mortality in 554 US women over a median period of
6 years (16). The former and latter studies on men and
women, respectively, reported a fourth quartile cut point of
6.9 and 2.8, respectively. Recent studies on TG/HDL-C have
reported that it is associated with long-term mortality in high-
risk individuals who have undergone percutaneous coronary
angiography (24), as well as the relevance of subclinical
coronary arterial calcification in low-risk individuals without
diabetes (12). However, these studies did not address sex
differences. Another study reported that TG/HDL-C, but not
the LDL-C to HDL-C ratio, in women has a significant
predictive value for CVD in a population-based cross-sectional
study, unlike in men (25). Therefore, it may be advantageous
for assessing and managing TG/HDL-C differently in men
and women.
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FIGURE 3 | Hazard ratios (95% CIs) for incident IHD according to TG/HDL-C quartiles after adjusting for potential confounding variables according to sex.
TABLE 5 | TG/HDL-C vs. metabolic syndrome and the number of metabolic syndrome components for predicting ischemic heart disease.
Pairwise comparison of AUC Classifying ability for ischemic heart disease
Difference 95% CI P-value Sensitivity (%) Specificity (%) AUC P-value
TG/HDL-C vs. metabolic syndrome 0.059 0.031 to 0.087 <0.001
TG/HDL-C vs. the number of
metabolic syndrome components
0.001 −0.025 to 0.027 0.929
The number of metabolic syndrome
components vs. metabolic
syndrome
0.064 0.037 to 0.083 <0.001
TG/HDL-C 64.2 52.1 0.607 <0.001
Metabolic syndrome 21.5 88.1 0.548 <0.001
The number of metabolic syndrome
components
79.1 37.4 0.608 <0.001
AUC, area under the receiver operating characteristic curve.
There was a noticeable increase and decrease in TG and HDL-
C, respectively, with insulin resistance progression; moreover,
the TG/HDL-c ratio is useful for assessing early insulin
resistance (6, 26). High TG and low HDL-C are the two most
common lipid abnormalities among Korean adults aged > 20
years, with a prevalence of approximately 28.7 and 41.2%,
respectively (27). The Korea National Health and Nutrition
Examination Survey indicated an increase in both high TG
and low HDL-C by > 30% in 2010 compared with 2007.
In the United States, ∼30 and 40% of adult men /women
in their 20’s and 30’s, respectively, have high TG and/or
low HDL-C (28). Individuals with insulin resistance are more
susceptible to atherosclerosis; moreover, coronary arterial disease
can develop and progress from early insulin resistance (5, 29).
The atherogenic link between TG/HDL-C and IHD, besides
insulin resistance, is associated with the generation of small,
dense LDL particles, which can cause vascular compromise (10,
30, 31). The NCEP guidelines for metabolic syndrome indicate
well-established sex differences in the HDL-C level (32). In the
same context, the TG/HDL-C ratio was significantly higher in
men; however, its association with IHD was more pronounced
in women.
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A major strength of our study was that this was a longitudinal
large-scale study linked to HIRA data, which are based on the
universal coverage system in Korea. This decreases the chance
of missing data. This study has several limitations. First, given
that the study cohort comprised volunteers for health promotion
screenings conducted at a single hospital, the participants
could have been slightly healthier than the general Korean
population. Moreover, some confounding variables, including
dietary data and traditional insulin resistance markers, may
have not been initially assessed. Second, some individuals with
diabetes may have been included in the final analysis since
glycated hemoglobin A1c assessment and oral glucose tolerance
tests were not performed at the beginning of the study.
CONCLUSIONS
An increased TG/HDL-C ratio precedes and significantly
predicts future IHD among community-dwelling Koreans.
Moreover, compared with metabolic syndrome, the TG/HDL-C
was a more powerful predictive indicator of IHD. Additionally,
there is a need to consider sex differences when interpreting
TG/HDL-C, even among individuals without diabetes. A high
TG/HDL-C ratio may be a useful indicator for assessing the CVD
risk in adults at the preclinical stage.
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